

FDA Issues Update to GLP-1 Product Labels

From NABP <news@nabp.pharmacy>

Date Wed 1/21/2026 7:10 PM


To Barron, Karin (DOH) <karin.barron@dc.gov>

CAUTION: This email originated from outside of the DC Government. Do not click on links or open attachments unless you recognize the sender and know that the content is safe. If you believe that this email is suspicious, please forward to phishing@dc.gov for additional analysis by OCTO Security Operations Center (SOC).



NABP WEEKLY

*Educational, Regulatory,
and Association News*



FDA Asks for Removal of Suicide Warnings From GLP-1 Products

Food and Drug Administration (FDA) has issued a request for manufacturers to remove the risk information concerning suicidal ideation and behavior from glucagon-like peptide-1 (GLP-1) receptor agonist products. This request applies to the following products: Saxenda® (liraglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide). The decision follows a comprehensive FDA analysis in which the agency did not find an increased risk of suicidal ideation and behavior in patients taking GLP-1 receptor agonist medications.

[Read FDA's Announcement](#)

FDA Approves New Narcan Carrying Case

FDA has approved a New Drug Application for a carrying case designed for Narcan® nasal spray, which will contain two doses of Narcan in the original packaging and a Quick Start Guide. According to the manufacturer, the case is intended to improve portability and address consumer preferences for discreet naloxone packaging. In a survey conducted by Emergent BioSolutions, Inc, 74% of respondents favored a discreet carrying case for naloxone over standard packaging. Separate [research](#) cited by the manufacturer indicates that approximately 11% of the public currently carry naloxone. Emergent BioSolutions did not provide a specific date as to when the carrying case will be available for purchase.

[Read About the New Product](#)

CDC Reports High Levels of Respiratory Illness Across US

[Centers for Disease Control and Prevention \(CDC\)](#) is reporting high levels of respiratory illness (influenza, COVID-19, and respiratory syncytial virus) activity across the United States. According to CDC's US

Influenza Surveillance Report, as of January 10, 2026, there has been a downward trend of positive tests for influenza.

The agency recommends individuals receive the annual flu vaccine this season.

[Read CDC's Influenza Surveillance Report](#)

Health System Barriers Contribute to Nonprescription Antibiotic Use

A recent study found that health care system barriers and patient beliefs both play a role in the nonprescription use of antibiotics. Researchers interviewed 86 participants from six public and two private clinics in Texas. Patients reported believing that antibiotics could relieve their symptoms, that they knew their own bodies, and that over-the-counter medications were ineffective. Many also viewed antibiotics as a valuable commodity. In addition, participants cited health care system obstacles, such as long wait times, transportation challenges, and limited access to care, as reasons for obtaining antibiotics without a prescription.

[Learn More About the Study](#)

New Mobile-Friendly Application Allows Patients to Choose Pharmacy for Filling Prescriptions

Electronic prescribing has become the norm in the US health system, not just an added convenience. In fact, approximately [**94% of prescriptions**](#) were filled electronically in 2021. However, real-world challenges still exist from varying system functions that can affect data quality and pharmacy workflow. To that end, Surescripts has launched Script Corner™, a mobile-friendly, web-based application that helps patients find affordable prescription medications across pharmacies. After a prescriber from a participating health system sends an electronic

prescription, **Script Corner** will generate a text message to the patient that will enable them to view their prescription information via a secure link. Patients will have the option to compare prices from other pharmacies and choose the pharmacy to which they prefer to send their prescription. If a patient does not open the link or choose a pharmacy within 15 minutes, the application will automatically send the prescription to the original pharmacy the patient selected. According to SureScripts' press release, all pharmacies are incorporated into Script Corner's system.

[See How Script Corner Will Support Pharmacies](#)

NABP Weekly is a publication prepared by NABP. Please send any comments, questions, or suggestions about the electronic newsletter to commdept@nabp.pharmacy.

We look forward to receiving your feedback.



National Association of Boards of Pharmacy®

[Unsubscribe](#)

This message was sent to karin.barron@dc.gov from news@nabp.pharmacy

NABP
National Association of Boards of Pharmacy
1600 Feehanville Dr
Mount Prospect, IL 60056